Valeant Pharmaceuticals has agreed to sell all outstanding equity interests in Dendreon Pharmaceuticals to a privately-owned Chinese conglomerate. Sanpower Group will pay $819.9 million for Dendreon’s only commercialized product called Provenge, a vaccine for prostate cancer treatment.